Dr. Jamin S. Brown, M.D.
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,119
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Perelman School of Med at the University of Pennsylvania
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
NY license 256631 -
Ophthalmology Physician
NY license 256631 · WA license ML20008129
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University Hospital S U N Y Health Science Center Syracuse, NY
Medical groups
- Ophthalmology Medical Service Group Inc (30 clinicians)
- Retina-Vitreous Surgeons of Central New York PC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,119
- Services billed
- 38,449
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 9,180 | 21 |
| Injection, aflibercept, 1 mg | 3,782 | 303 |
| Imaging of retina | 2,988 | 839 |
| Injection of drug into eye | 2,030 | 365 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 960 | 33 |
| Established patient complete exam of visual system | 423 | 349 |
| Established patient office or other outpatient visit, 30-39 minutes | 391 | 296 |
| Injection, ranibizumab, 0.1 mg | 373 | 15 |
| Established patient office or other outpatient visit, 20-29 minutes | 191 | 146 |
| New patient complete exam of visual system | 105 | 105 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Liverpool, NY | 259 |
| Tobramycin | 154 |
| Timolol Maleate Other prescribers in Liverpool, NY | 116 |
| Ketorolac Tromethamine Other prescribers in Liverpool, NY | 104 |
| Latanoprost Other prescribers in Liverpool, NY | 95 |
| Brimonidine Tartrate Other prescribers in Liverpool, NY | 28 |
| Bromfenac Sodium | 26 |
| Diclofenac Sodium Other prescribers in Liverpool, NY | 19 |
| Difluprednate | 18 |
| Erythromycin (erythromycin base) Other prescribers in Liverpool, NY | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $318 in total to this clinician.
| Alcon Vision LLC | $133 |
|---|---|
| Amgen Inc. | $125 |
| Regeneron Healthcare Solutions, Inc. | $39.33 |
| Astellas Pharma US Inc | $20.61 |
| Food and Beverage | $318 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 5 companies. The companies reported $303,750 in research payments for these studies, mostly to the institutions running them.
- A phase 2, multicenter, randomized, double-masked, parallel-group study to assess the efficacy and safety of KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with diabetic macular edema
Kyowa Kirin, Inc. - A Phase 1 SAD MD in Diabetic Macular Edema
Genentech, Inc. - A phase 2, multicenter, randomized, double-masked, parallel group study to assess the efficacy and safety of KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with neovascular age-related m…
Kyowa Kirin, Inc. - Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - MAD to assess the safety tolerability and PK PD in nAMD patients
Genentech, Inc. - Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy …
Janssen Research & Development, LLC - A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy …
Janssen Research & Development, LLC - Port Delivery System of Ranibizumab Extension Study
Genentech, Inc. - Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.